10:01 EST Sana Biotechnology trading resumes
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SANA:
- Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
- Sana Biotechnology announces FDA clearance of IND application for SC262
- Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Sana Biotechnology highlights preclinical data on allogeneic CAR T cells
- Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting